Telotristat etiprate - Lexicon Pharmaceuticals

Drug Profile

Telotristat etiprate - Lexicon Pharmaceuticals

Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Xermelo

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin modulators; TPH1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 30 Jul 2018 Lexicon Pharmaceuticals plans a clinical trial for Cancer in second half of 2018
  • 04 May 2018 Updated efficacy data from the phase III TELESTAR and trial in Malignant carcinoid released by Ipsen
  • 23 Apr 2018 Ipsen initiates enrolment in a phase I pharmacokinetics study in Renal impairement patients in Romania after February 2018 (NCT03442725)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top